GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » 3-Year ROIIC %

Innovus Pharmaceuticals (Innovus Pharmaceuticals) 3-Year ROIIC % : 0.00% (As of Dec. 2018)


View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Innovus Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2018 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Innovus Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:

INNV's 3-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.455
* Ranked among companies with meaningful 3-Year ROIIC % only.

Innovus Pharmaceuticals 3-Year ROIIC % Historical Data

The historical data trend for Innovus Pharmaceuticals's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals 3-Year ROIIC % Chart

Innovus Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Innovus Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovus Pharmaceuticals's 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Innovus Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovus Pharmaceuticals's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innovus Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Innovus Pharmaceuticals's 3-Year ROIIC % falls into.



Innovus Pharmaceuticals 3-Year ROIIC % Calculation

Innovus Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2018 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -5.692 (Dec. 2018) - -2.978611 (Dec. 2015) )/( 9.81 (Dec. 2018) - 8.297 (Dec. 2015) )
=-2.713389/1.513
=-179.34%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Innovus Pharmaceuticals  (OTCPK:INNV) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Innovus Pharmaceuticals 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
8845 Rehco Road, San Diego, CA, USA, 92121
Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.
Executives
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu director
Henry Jemil Esber director 38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz officer: EVP, CORPORATE DEVELOPMENT 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn officer: VP, CFO 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj director, officer: CHIEF EXECUTIVE OFFICER C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman officer: Chief Financial Officer ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown officer: See remarks 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew director 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness director, officer: Secretary 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack director, 10 percent owner, officer: President & CEO 175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111